The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study
Open accessAbstract
BACKGROUND: Having opioid dependence and HIV infection are associated with poor HIV-related treatment outcomes. METHODS: HIV-infected, opioid-dependent subjects (N = 295) recruited from 10 clinical sites initiated buprenorphine/naloxone (BUP/NX) and were assessed at baseline and quarterly for 12 months. Primary outcomes included receiving antiretroviral therapy (ART), HIV-1 RNA suppression, and mean changes in CD4 lymphocyte count. Analyses were stratified for the 119 subjects not on ART at baseline. Generalized estimating equations were deployed to examine time-dependent correlates for each outcome. RESULTS: At baseline, subjects on ART (N = 176) were more likely than those not on ART (N = 119) to be older, heterosexual, have lower alcohol addiction severity scores, and lower HIV-1 RNA levels; they were less likely to be homeless and report sexual risk behaviors. Subjects initiating BUP/NX (N = 295) were significantly more likely to initiate or remain on ART and improve CD4 counts over time compared with baseline; however, these improvements were not significantly improved by longer retention on BUP/NX. Retention on BUP/NX for three or more quarters was, however, significantly associated with increased likelihood of initiating ART (β = 1.34 [1.18, 1.53]) and achieve viral suppression (β = 1.25 [1.10, 1.42]) for the 64 of 119 (54%) subjects not on ART at baseline compared with the 55 subjects not retained on BUP/NX. In longitudinal analyses, being on ART was positively associated with increasing time of observation from baseline and higher mental health quality of life scores (β = 1.25 [1.06, 1.46]) and negatively associated with being homo- or bisexual (β = 0.55 [0.35, 0.97]), homeless (β = 0.58 [0.34, 0.98]), and increasing levels of alcohol addiction severity (β = 0.17 [0.03, 0.88]). The strongest correlate of achieving viral suppression was being on ART (β = 10.27 [5.79, 18.23]). Female gender (β = 1.91 [1.07, 3.41]), Hispanic ethnicity (β = 2.82 [1.44, 5.49]), and increased general health quality of life (β = 1.02 [1.00,1.04]) were also independently correlated with viral suppression. Improvements in CD4 lymphocyte count were significantly associated with being on ART and increased over time. CONCLUSIONS: Initiating BUP/NX in HIV clinical care settings is feasible and correlated with initiation of ART and improved CD4 lymphocyte counts. Longer retention on BPN/NX was not associated with improved prescription of ART, viral suppression, or CD4 lymphocyte counts for the overall sample in which the majority was already prescribed ART at baseline. Among those retained on BUP/NX, HIV treatment outcomes did not worsen and were sustained. Increasing time on BUP/NX, however, was especially important for improving HIV treatment outcomes for those not on ART at baseline, the group at highest risk for clinical deterioration. Retaining subjects on BUP/NX is an important goal for sustaining HIV treatment outcomes for those on ART and improving them for those who are not. Comorbid substance use disorders (especially alcohol), mental health problems, and quality-of-life indicators independently contributed to HIV treatment outcomes among HIV-infected persons with opioid dependence, suggesting the need for multidisciplinary treatment strategies for this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The fifth edition of the addiction severity index
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,222
McLELLAN, A. T., LUBORSKY, L., WOODY, G. E., & O??BRIEN, C. P. (1980) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198001000-00006 · Cited by 3,188
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
Granich, R. M., Gilks, C. F., Dye, C., De Cock, K. M., & Williams, B. G. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61697-9 · Cited by 1,988
Egger, M., May, M., Chêne, G., Phillips, A. N., Ledergerber, B., Dabis, F., Costagliola, D., Monforte, A. D., de Wolf, F., Reiss, P., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09411-4 · Cited by 1,525
Masur, H., Michelis, M. A., Greene, J. B., Onorato, I., Vande Stouwe, R. A., Holzman, R. S., Wormser, G., Brettman, L., Lange, M., Murray, H. W., et al. (1981) · New England Journal of Medicine · doi:10.1056/nejm198112103052402 · Cited by 1,434
Bertholet, N. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.9.986 · Cited by 710
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
(2010) · Clinical Infectious Diseases · doi:10.1086/652283 · Cited by 594
Altice, F. L., Kamarulzaman, A., Soriano, V. V., Schechter, M., & Friedland, G. H. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60829-x · Cited by 504
Self-citationAzar, M. M., Springer, S. A., Meyer, J. P., & Altice, F. L. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.06.014 · Cited by 394 · cited 13×
“Table 1 provides the baseline characteristics of the 295 subjects who initiated BUP/NX and were stratified by those who were on and not on ART.”
BackgroundResultInfluentialSelf-citationChander, G., Himelhoch, S., & Moore, R. D. (2006) · Drugs · doi:10.2165/00003495-200666060-00004 · Cited by 379
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection
Baker, J. V., Peng, G., Rapkin, J., Abrams, D. I., Silverberg, M. J., MacArthur, R. D., Cavert, W. P., Henry, W. K., & Neaton, J. D. (2008) · AIDS · doi:10.1097/qad.0b013e3282f7cb76 · Cited by 372
Amato, L., Minozzi, S., Davoli, M., & Vecchi, S. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004147.pub4 · Cited by 370
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R., Kimber, J., Breen, C., & Davoli, M. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub2 · Cited by 360
Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence
Mannheimer, S. B., Matts, J., Telzak, E., Chesney, M., Child, C., Wu, A. W., Friedland, G., & Progr, F. T. T. B. C. (2005) · AIDS Care · doi:10.1080/09540120412331305098 · Cited by 331
Lucas, G. M., Gebo, K. A., Chaisson, R. E., & Moore, R. D. (2002) · AIDS · doi:10.1097/00002030-200203290-00012 · Cited by 320
Self-citationLima, V. D., Harrigan, R., Bangsberg, D. R., Hogg, R. S., Gross, R., Yip, B., & Montaner, J. S. G. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31819675e9 · Cited by 304
Advancing HIV Prevention: New Strategies for a Changing Epidemic—United States, 2003
(2003) · JAMA · doi:10.1001/jama.289.19.2493 · Cited by 293
. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.
Tien, P. C., Choi, A. I., Zolopa, A. R., Benson, C., Tracy, R., Scherzer, R., Bacchetti, P., Shlipak, M., & Grunfeld, C. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181e66216 · Cited by 279
Applications of the medical outcomes study health-related quality of life measures in HIV/AIDS
Wu, A. W., Hays, R. D., Kelly, S., Malitz, F., & Bozzette, S. A. (1997) · Quality of Life Research · doi:10.1023/a:1018460132567 · Cited by 269
Crack-Cocaine Use Accelerates HIV Disease Progression in a Cohort of HIV-Positive Drug Users
Baum, M. K., Rafie, C., Lai, S., Sales, S., Page, B., & Campa, A. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181900129 · Cited by 255
The Addiction Severity Index A field study of internal consistency and validity
Leonhard, C., Mulvey, K., Gastfriend, D. R., & Shwartz, M. (2000) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(99)00025-2 · Cited by 240
Leaver, C. A., Bargh, G., Dunn, J. R., & Hwang, S. W. (2007) · AIDS and Behavior · doi:10.1007/s10461-007-9246-3 · Cited by 222
Kidder, D. P., Wolitski, R. J., Campsmith, M. L., & Nakamura, G. V. (2007) · American Journal of Public Health · doi:10.2105/ajph.2006.090209 · Cited by 209
Parienti, J.-J., Das-Douglas, M., Massari, V., Guzman, D., Deeks, S. G., Verdon, R., & Bangsberg, D. R. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002783 · Cited by 204
Advancing HIV prevention: new strategies for a changing epidemic--United States, 2003.
(2003) · PubMed · Cited by 190
A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence
Johnson, R. E., Eissenberg, T., Stitzer, M. L., Strain, E. C., Liebson, I. A., & Bigelow, G. E. (1995) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(95)01186-2 · Cited by 183
Decroo, T., Telfer, B., Biot, M., Maïkéré, J., Dezembro, S., Cumba, L. I., das Dores, C., Chu, K., & Ford, N. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182055138 · Cited by 182
Housing Need, Housing Assistance, and Connection to HIV Medical Care
Aidala, A. A., Lee, G., Abramson, D. M., Messeri, P., & Siegler, A. (2007) · AIDS and Behavior · doi:10.1007/s10461-007-9276-x · Cited by 169
Mellins, C. A., Havens, J. F., McDonnell, C. J., Lichtenstein, C., Uldall, K. K., Chesney, M. A., Santamaria, E. K., & Bell, J. (2009) · AIDS Care · doi:10.1080/09540120802001705 · Cited by 160
Antiretroviral medication adherence and the development of class-specific antiretroviral resistance
Gardner, E. M., Burman, W. J., Steiner, J. F., Anderson, P. L., & Bangsberg, D. R. (2009) · AIDS · doi:10.1097/qad.0b013e32832ba8ec · Cited by 160
Neurocognitive Impairment and HIV Risk Factors: A Reciprocal Relationship
Anand, P., Springer, S. A., Copenhaver, M. M., & Altice, F. L. (2010) · AIDS and Behavior · doi:10.1007/s10461-010-9684-1 · Cited by 154
Self-citationOffice-Based Treatment of Opioid-Dependent Patients
Fiellin, D. A., & O'Connor, P. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp013579 · Cited by 148
Self-citationPetersen, M. L., Wang, Y., van der Laan, M. J., Guzman, D., Riley, E. D., & Bangsberg, D. R. (2007) · Clinical Infectious Diseases · doi:10.1086/521250 · Cited by 144
History and current status of opioid maintenance treatments: blending conference session
Kreek, M. J., & Vocci, F. J. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00259-3 · Cited by 131
Determinants of health-related quality of life in HIV-infected patients
Murri, R., Fantoni, M., Borgo, C. D., Visonà, R., Barracco, A., Zambelli, A., Testa, L., Orchi, N., Tozzi, V., Bosco, O., et al. (2003) · AIDS Care · doi:10.1080/0954012031000134818 · Cited by 126
Lucas, G. M., Chaudhry, A. A., Hsu, J., Woodson, T., Lau, B. M., Olsen, Y. K., Keruly, J. C., Fiellin, D. A., Finkelstein, R., Barditch‐Crovo, P., et al. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00003 · Cited by 119
Self-citationRoux, P., Carrieri, P., Cohen, J., Ravaux, I., Poizot‐Martin, I., Dellamonica, P., & Spire, B. (2009) · Clinical Infectious Diseases · doi:10.1086/630209 · Cited by 115
Fisher, J. D., Cornman, D. H., Osborn, C. Y., Amico, K. R., Fisher, W. A., & Friedland, G. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000140605.51640.5c · Cited by 111
Report of the Council on Scientific Affairs
Yoast, R. A., Williams, M. A., Deitchman, S. D., & Champion, H. C. (2001) · Journal of Addictive Diseases · doi:10.1300/j069v20n02_03 · Cited by 105
Consensus statement on office-based treatment of opioid dependence using buprenorphine
Fiellin, D. A., Kleber, H. D., Trumble, J. G., McLellan, A. T., & Kosten, T. R. (2004) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2004.06.005 · Cited by 99
Self-citationTreatment of heroin dependence with buprenorphine in primary care
Fiellin, D. A., Pantalon, M. V., Pakes, J. P., O'Connor, P. G., Chawarski, M., & Schottenfeld, R. S. (2002) · The American Journal of Drug and Alcohol Abuse · doi:10.1081/ada-120002972 · Cited by 98
Self-citationClinical Care of the HIV-Infected Drug User
Bruce, R. D., & Altice, F. L. (2007) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2007.03.009 · Cited by 94
Self-citationTreatment of Heroin Addicts Using Buprenorphine
Kosten, T. R., Morgan, C., & Kleber, H. D. (1991) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952999108992815 · Cited by 87
Lodwick, R. K. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60932-4 · Cited by 84
Interventions to Improve Adherence to Antiretroviral Therapy
Tuldrà, A., & Wu, A. W. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200212153-00014 · Cited by 80
Pence, B. W., Ostermann, J., Kumar, V., Whetten, K., Thielman, N. M., & Mugavero, M. J. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31815ace7e · Cited by 79
Weiss, L., Netherland, J. C., Egan, J. E., Flanigan, T., Fiellin, D. A., Finkelstein, R., & Altice, F. L. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31820a8226 · Cited by 78
Self-citationRoyal, S., Kidder, D. P., Patrabansh, S., Wolitski, R. J., Holtgräve, D. R., Aidala, A. A., Pals, S. L., & Stall, R. D. (2009) · AIDS Care · doi:10.1080/09540120802270250 · Cited by 76
Adherence to HIV Antiretrovirals among Persons with Serious Mental Illness
Wagner, G. J., Kanouse, D. E., Koegel, P., & Sullivan, G. (2003) · AIDS Patient Care and STDs · doi:10.1089/108729103321619782 · Cited by 74
An Investigation of Why Eligible Patients Do Not Receive HAART
Maisels, L., Steinberg, J., & Tobias, C. R. (2001) · AIDS Patient Care and STDs · doi:10.1089/10872910151133701 · Cited by 71
Wong, M. D., Cunningham, W. E., Shapiro, M. F., Andersen, R., Cleary, P. D., Duan, N., Liu, H. H., Wilson, I. B., Landon, B. E., & Wenger, N. S. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30429.x · Cited by 70
Korthuis, P. T., Tozzi, M. J., Nandi, V., Fiellin, D. A., Weiss, L., Egan, J. E., Botsko, M., Acosta, A., Gourevitch, M. N., Hersh, D., et al. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318209754c · Cited by 66
Self-citationModels for Integrating Buprenorphine Therapy into the Primary HIV Care Setting
Basu, S., Smith-Rohrberg, D., Bruce, R. D., & Altice, F. L. (2006) · Clinical Infectious Diseases · doi:10.1086/500200 · Cited by 57
Self-citationAmato, L., Minozzi, S., Davoli, M., Vecchi, S., Ferri, M., & Mayet, S. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004147.pub3 · Cited by 57
Preventing HIV transmission with antiretrovirals
Crowley, S. (2009) · Bulletin of the World Health Organization · doi:10.2471/blt.09.067330 · Cited by 56
Kohli, R., Lo, Y., Howard, A. A., Buono, D. L., Floris-Moore, M., Klein, R. S., & Schoenbaum, E. E. (2005) · Clinical Infectious Diseases · doi:10.1086/432883 · Cited by 54
Office-Based Treatment for Opioid Dependence: Reaching New Patient Populations
Fiellin, D. A., Rosenheck, R. A., & Kosten, T. R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1200 · Cited by 53
Self-citationProvider barriers to prescribing HAART to medically-eligible HIV-infected drug users
Loughlin, A. M., Metsch, L. R., Gardner, L. I., Anderson-Mahoney, P. J., Barrigan, M., & Strathdee, S. A. (2004) · AIDS Care · doi:10.1080/09540120410001683411 · Cited by 51
Kim, T. W., Palepu, A., Cheng, D. M., Libman, H., Saitz, R., & Samet, J. H. (2007) · AIDS Care · doi:10.1080/09540120701294245 · Cited by 50
Springer, S. A., Chen, S., & Altice, F. L. (2009) · AIDS Care · doi:10.1080/09540120802657555 · Cited by 47
Self-citationAltice, F. L., Sullivan, L. E., Smith-Rohrberg, D., Basu, S., Stancliff, S., & Eldred, L. J. (2006) · Clinical Infectious Diseases · doi:10.1086/508181 · Cited by 44
Self-citationCheever, L. W., Kresina, T. F., Cajina, A., & Lubran, R. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318209740f · Cited by 30
Self-citation
Cited by
Thompson, M. A., Mugavero, M. J., Amico, K. R., Cargill, V. A., Chang, L. W., Gross, R., Orrell, C., Altice, F. L., Bangsberg, D. R., Bartlett, J. G., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-11-201206050-00419 · Cited by 582
Self-citationAidala, A. A., Wilson, M. G., Shubert, V., Gogolishvili, D., Globerman, J., Rueda, S., Bozack, A. K., Caban, M., & Rourke, S. B. (2016) · American Journal of Public Health · doi:10.2105/ajph.2015.302905 · Cited by 418
Menendez, M. E., Ring, D., & Bateman, B. T. (2015) · Clinical Orthopaedics & Related Research · doi:10.1007/s11999-015-4173-5 · Cited by 340
Primary Care–Based Models for the Treatment of Opioid Use Disorder: A Scoping Review
Korthuis, P. T., McCarty, D., Weimer, M., Bougatsos, C., Blazina, I., Zakher, B., Grusing, S., Devine, B., & Chou, R. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2149 · Cited by 297
Self-citationKrishnan, A., Ferro, E. G., Weikum, D., Vagenas, P., Lama, J. R., Sanchez, J., & Altice, F. L. (2015) · AIDS Care · doi:10.1080/09540121.2014.963014 · Cited by 50
“…who might be targets for future intervention, specifically those meeting criteria for AUD, depression, and optimal ART adherence, all of which are associated with poor HIV treatment outcomes (Altice et al., 2011; Maru et al., 2008; Wood, Hogg, et al., 2004; Wood, Montaner, et al., 2004).”
BackgroundSelf-citation
Metadata
- Authors
- Altice, F. L., Bruce, R. D., Lucas, G. M., Lum, P. J., Korthuis, P. T., Flanigan, T. P., Cunningham, C. O., Sullivan, L. E., Vergara-Rodriguez, P., Fiellin, D. A., Cajina, A., Botsko, M., Nandi, V., Gourevitch, M. N., & Finkelstein, R.
- Venue
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2011-03-01
- Volume
- 56
- Issue
- Supplement 1
- Pages
- S22-S32
- ISSN
- 1525-4135 (ISSN-L)
- OpenAlex
- W2023613783
- Cited by
- 256
- References
- 65
- FWCI
- 16.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.